EuroPCR: Edwards will carry on in transcatheter mitral valve space despite Fortis snag
This article was originally published in Clinica
Executive Summary
Edwards Lifesciences has hit a snag with its transcatheter mitral valve program after it voluntarily paused a clinical trial of its investigational Fortis valve. The firm has seen “evidence of valve thrombosis that we believe warrants additional investigation.”